Fosters Research
No Result
View All Result
No Result
View All Result
Fosters Research
No Result
View All Result
Home Analyst Opinions

Ocugen Inc. (OCGN): What Top Wall Street Players are Saying

August 29, 2022
in Analyst Opinions

Mizuho Securities believes biotech firm Ocugen Inc. (NASDAQ: OCGN) is undervalued. Its business prospects extend beyond the development of a COVID-19 vaccine.

According to Mizuho, Ocugen is now being evaluated exclusively on the commercial possibilities of its COVID-19 vaccine, which is already licensed for adult use in Mexico and is being reviewed by Canadian regulators. However, Ocugen’s portfolio has a promising product that has the potential to generate hundreds of millions of dollars in sales.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

We’re talking about OCU400, a potential therapy for eye problems. This candidate is a gene therapy modification with the goal of treating the early and middle phases of retinitis pigmentosa, a genetic illness that causes vision impairment and eventually blindness. Symptoms of the condition develop at various ages, but the earlier therapy begins, the less severe the effects.

If the OCU400 candidate survives all phases of testing and wins regulatory approval, it might generate Ocugen Inc. (OCGN) several hundred million dollars in sales. The application to the authorities is expected to be presented in two to three years, assuming that the research and testing go as planned.

Analysts at Mizuho predict that OCU400 will be the most successful medicine in the Ocugen Inc. (OCGN) family. As a result, the company’s analysts raised the target price for OCGN shares to $5, about double the current price, and issued a recommendation to “buy” shares this week. Analysts believe that the market is now overlooking a crucial value proposition from Ocugen.

At the same time, risks must be considered, because even promising candidates in the early phases of development may not always reach the desired outcomes in the later stages. As a result, despite the fact that Ocugen Inc. (OCGN) already has a commercial product – the Covaxin vaccination against COVID-19 – investing in the firm remains hazardous.

OCGN stock gained 10.55% in the previous week and 7.60% in the previous month. This company’s stock increased 30.41% in the previous quarter. The stock has been down -7.36% in the previous six months, with a year-to-date loss of -63.15%. At the time of writing, the year-to-date (YTD) price performance of this stock was -37.80%.

Tags: NASDAQ: OCGNOCGNOCGN STOCKOCGN STOCK PRICEOcugen

Related Posts

What Led The Verona Pharma (VRNA) Stock To Increase 34% Pre-Market?

December 20, 2022

Top Ratings Upgrades for December 1: Avadel Pharmaceuticals (AVDL), Cooper Companies (COO), SoundHound AI (SOUN)

December 1, 2022

5 Hot Pre-Market Movers Stock to Watch

November 11, 2022

IMAC Holdings (BACK) Stock Rose nearly 19% Pre-Hours. How Did That Happen?

October 26, 2022

What Happened On Thursday To Make Guardion Health (GHSI) Stock Surge?

October 6, 2022

Why Is 9 Meters Biopharma (NMTR) Stock Increasing Pre-Market Today?

September 27, 2022
Next Post

Confluent Inc. (CFLT): What Top Wall Street Players are Saying

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Could Calumet Specialty Products Partners L.P. (CLMT) stock price achieve new all-time highs if its expected earnings and revenue increase?

3 months ago

When is the right time to cash out of TriNet Group Inc. [TNET] stock?

3 months ago

Can Domino’s Pizza Inc. (DPZ) stock recover despite sales dropping?

1 week ago

Reasons why Interactive Brokers Group Inc.’s (NASDAQ:IBKR) fundamentals are futile

1 month ago
logo

Welcome to Fosters Research.
We provide quality information for free in a convenient place and format. You do not need to look for us – the news portal “Fosters Research” meets the reader every morning.

Categories

  • Analyst Opinions
  • Featured
  • Finance
  • Market News
  • Technical Indicators
  • Trending Stocks

Company

  • Home
  • About us
  • Contact

Recent Posts

  • Can Titan Pharmaceuticals Inc. (TTNP) stock recover despite sales dropping?
  • There is little time left for S&T Bancorp Inc. (STBA) to reach its 1-year target estimate. How soon will it surpass it?

Copyright © 2022 fostersresearch

No Result
View All Result
  • Home
  • Analyst Opinions
  • Market News
  • Technical Indicators
  • Trending Stocks

Copyright © 2022 fostersresearch